Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

Aptose Upgraded to Trade on OTCQB Market

European Hematology Association Congress (EHA 2025)

Jun 12, 2025 • 5:00 pm - 6:15 pm CEST

2025 Annual and Special Meeting of Shareholders

May 27, 2025 • 10:00 am EDT